Tositumomab
From Wikipedia, the free encyclopedia
|
Tositumomab
|
|
|
|
|
| Source | Mouse |
| Target | CD20 |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| DrugBank | |
| Chemical data | |
| Formula | C6416H9874N1688O1987S44 |
| Mol. mass | 143859.7 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Tositumomab is a monoclonal antibody derived from immortalized mouse cells. It is a IgG2a anti-CD20 antibody and is covalently bound to Iodine 131. 131I emits both beta and gamma radiation, and is broken down rapidly in the body.
Clinical trials have established the efficacy of tositumomab in patients with relapsed or chemotherapy/rituxan refractory follicular lymphoma.
It is manufactured by Corixa. It sells in the U.S. under the trade name Bexxar.
Abagovomab, Afelimomab, Altumomab, Anatumomab mafenatox, Arcitumomab, Bectumomab, Besilesomab, Biciromab brallobarbital, Capromab, Detumomab, Dorlimomab aritox, Edobacomab, Edrecolomab, Elsilimomab, Enlimomab, Enlimomab pegol, Epitumomab, Epitumomab cituxetan, Fanolesomab, Faralimomab, Gavilimomab, Ibritumomab tiuxetan, Igovomab, Imciromab, Inolimomab, Lemalesomab, Maslimomab, Minretumomab, Mitumomab, Nacolomab tafenatox, Nerelimomab, Nofetumomab merpentan, Odulimomab, Oregovomab, Pemtumomab, Pintumomab, Satumomab, Sulesomab, Taplitumomab paptox, Telimomab aritox, Tositumomab, Vepalimomab, Zolimomab aritox
 |
This medical treatment article is a stub. You can help Wikipedia by expanding it. |
